文献速递青光眼白内障与屈光手术

iStent联合白内障手术后降眼压药物使用减少

Ocular Antihypertensive Medication Use After iStent Implantation Concurrent With Cataract Surgery vs Cataract Surgery Alone in a Large US Health Care Claims Database.
PubMed 文献 · JAMA Ophthalmol · 2019-01-01

基于美国医保索赔数据库的回顾性队列研究,比较iStent联合白内障手术与单纯白内障手术患者术后使用局部降眼压药物的变化。结果显示联合手术组术后无药比例更高,基线用药≥3种者持续减药可能性更大,但仅22.8%患者完成至少2年随访。

要点

  • iStent联合白内障手术与术后局部降眼压药物使用中度减少相关。
  • 基线用药≥3种者较1种者更可能持续减药(HR 1.68,95%CI 1.36-2.09)。
  • 联合手术组术后20-24月无药比例73.5%,高于对照组的55.3%。

核心结论

  • iStent联合白内障手术与局部降眼压药物使用中度减少相关。
  • 减少用药可能减轻药物不良反应负担并促进依从性。

研究设计与样本

  • 回顾性观察性纵向队列研究,数据来自美国管理式医疗网络索赔数据库。
  • iStent联合白内障手术组2012-2016年双侧1509例、单侧1462例,双侧组与单纯白内障手术组1:1匹配。
  • 共2971例符合条件入组者,首次手术平均年龄74.3岁,女性1659例(55.8%)。

主要发现

  • iStent/CEIOL组诊断包括原发性开角型青光眼2329例(78.4%)、窄角381例(12.8%)、继发性青光眼261例(8.8%)。
  • 基线时1223例(41.2%)未用局部降眼压药,876例(29.5%)、437例(14.7%)、435例(14.6%)分别用1、2、≥3种药物。
  • 仅678例(22.8%)完成至少2年术后随访;术后20-24个月无药比例增至64.7%(P<.001,χ2)。
  • 基线至少用1种药物者,双侧或单侧手术在20-24个月平均减少1.01和0.61种药物(均P<.001,配对t检验)。
  • 与匹配的单纯白内障手术组相比,双侧iStent/CEIOL组术后20-24个月平均减药更多(0.99 vs 0.49;P<.001;配对t)且无药比例更高(73.5% vs 55.3%;P<.001;χ2)。

临床怎么用

  • 对于需联合白内障手术的青光眼患者,iStent植入可考虑用于减少局部降眼压药物使用。
  • 基线用药负担较重者可能从联合手术中持续减药获益更明显。

局限性

  • 仅22.8%患者完成至少2年术后随访,长期数据有限。
  • 回顾性索赔数据库研究可能存在混杂和未测量偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The iStent Trabecular Micro-Bypass (Glaukos Corporation) is a minimally invasive glaucoma implant used in conjunction with cataract surgery to lower intraocular pressure. OBJECTIVE: To determine whether implantation of the iStent concurrent with cataract surgery is associated with reduced use of ocular antihypertensive medications in a US health care claims database. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, observational longitudinal cohort study of individuals enrolled in a US managed care network who underwent iStent implantation with cataract surgery (iStent/CEIOL) from 2012 to 2016 (n = 1509 bilateral and n = 1462 unilateral surgery). A control group of individuals who underwent bilateral cataract surgery only (CEIOL) were matched 1:1 to patients undergoing bilateral iStent/CEIOL on baseline demographic and clinical factors. Data were analyzed between November 1, 2017, and January 31, 2018. MAIN OUTCOMES AND MEASURES: The number of topical ocular antihypertensive agents used postoperatively by patients undergoing iStent/CEIOL compared with baseline and with matched CEIOL control individuals, and hazard ratios with 95% confidence intervals for sustained reduced use of at least 1 topical ocular antihypertensive agent postoperatively. RESULTS: Of the 2971 eligible enrollees, mean age at first surgery was 74.3 years, and 1659 (55.8%) were women. Patients undergoing iStent/CEIOL had diagnoses that included primary open-angle glaucoma (n = 2329; 78.4%), narrow angles (n = 381; 12.8%), and secondary glaucomas (n = 261; 8.8%). At baseline, 1223 (41.2%) were receiving no topical glaucoma agents; 876 (29.5%), 437 (14.7%), and 435 (14.6%) were receiving 1, 2, or at least 3 agents, respectively. Although only 678 persons (22.8%) completed at least 2 years of postoperative follow-up, the proportion of patients receiving no drops increased postoperatively (64.7%, 20-24 months, P < .001, χ2). Patients receiving at least 1 topical agent at baseline had mean reduction of 1.01 and 0.61 medications used at 20 to 24 months with bilateral or unilateral surgery, respectively (both P < .001, paired t). Sustained reduction in glaucoma medication use was more likely in patients receiving at least 3 vs 1 medication at baseline (hazard ratio, 1.68; 95% CI, 1.36-2.09). Compared with matched control individuals undergoing CEIOL, patients undergoing bilateral iStent/CEIOL had a greater mean reduction in drops used (0.99 vs 0.49; postoperative month 20-24; P < .001; paired t) and a higher proportion receiving no drops postoperatively (73.5% vs 55.3%, postoperative month 20-24; P < .001; χ2). CONCLUSIONS AND RELEVANCE: Implantation of the iStent trabecular micro-bypass stent concurrent with cataract surgery was associated with moderately reduced use of topical ocular antihypertensive medication. Reduction in the use of glaucoma medications may lessen the burden of medication adverse effects and promote better adherence.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wang SY, Singh K, Stein JD, et al. Ocular Antihypertensive Medication Use After iStent Implantation Concurrent With Cataract Surgery vs Cataract Surgery Alone in a Large US Health Care Claims Database. JAMA Ophthalmol. 2019. PMID: 30267072. doi:10.1001/jamaophthalmol.2018.4461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。